Yahoo Finance • 13 days ago
Axsome Therapeutics recently presented six clinical and real-world neuroscience data posters at the 38th Annual Psych Congress in San Diego, with a focus on major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstruct... Full story
Yahoo Finance • 16 days ago
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced six presentations across its... Full story
Yahoo Finance • 20 days ago
SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential violations of federal and state laws by certain officers of the following companies: General Motors Company (NYSE: GM), DocGo Inc. (NASDAQ: DCG... Full story
Yahoo Finance • last month
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in t... Full story
Yahoo Finance • last month
By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by prelimi... Full story
Yahoo Finance • 2 months ago
Axsome Therapeutics Inc. (AXSM) reported its second-quarter 2025 earnings, surpassing Wall Street expectations. The company posted an earnings per share (EPS) of -$0.97, outperforming the forecast of -$1.06. Revenues reached $150 million,... Full story
Yahoo Finance • 2 months ago
Axsome Therapeutics Inc (NASDAQ:AXSM [https://www.chartmill.com/stock/quote/AXSM]) reported second-quarter 2025 financial results, delivering revenue that exceeded analyst expectations while narrowing its earnings per share (EPS) loss comp... Full story
Yahoo Finance • 2 months ago
September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.64%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are up +0.77% this morning, po... Full story
Yahoo Finance • 2 months ago
Major earnings expected before the bell on Monday include: * Transocean Ltd. (RIG [https://seekingalpha.com/symbol/RIG]) * ON Semiconductor Corporation (ON [https://seekingalpha.com/symbol/ON]) * BioNTech SE (BNTX [https://seekingal... Full story
Yahoo Finance • 2 months ago
Comprehensive review of broad pipeline targeting Alzheimer’s disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company... Full story
Yahoo Finance • 3 months ago
[Close up of buildings in Wall Street] Alphotographic Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MON... Full story
Yahoo Finance • 3 months ago
[Top Prospects Most Profitable Stock Market Best Investments 3d Illustration] iQoncept/iStock via Getty Images UBS analysts listed top and bottom-ranked stocks based on a key set of drivers for equities, they named REVS. UBS’s REVS frame... Full story
Yahoo Finance • 3 months ago
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial... Full story
Yahoo Finance • 3 months ago
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontie... Full story
Yahoo Finance • 3 months ago
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer’s disease... Full story
Yahoo Finance • 3 months ago
Hunter R. Murdock, General Counsel at Axsome Therapeutics, Inc. (NASDAQ:AXSM), sold a total of 22,500 shares of common stock for approximately $2.28 million, between June 16 and June 18, 2025. The sales were executed at weighted average pr... Full story
Yahoo Finance • 4 months ago
Axsome Therapeutics, Inc. (NASDAQ:AXSM), with a market capitalization of $5.14 billion and impressive year-to-date returns of 23%, has positioned itself as a prominent player in the central nervous system (CNS) disorders market, with a div... Full story
Yahoo Finance • 4 months ago
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, includin... Full story
Yahoo Finance • 4 months ago
(RTTNews) - Axsome Therapeutics, Inc. (AXSM) has announced the U.S. prescription availability of SYMBRAVO, a new oral medication combining meloxicam and rizatriptan for the acute treatment of migraine with or without aura in adults. The t... Full story
Yahoo Finance • 4 months ago
[FDA - Food and Drug Administration text on document above brown envelope and stethoscope. Healthcare or medical concept] syahrir maulana/iStock via Getty Images Shares of Axsome Therapeutics (NASDAQ: NASDAQ:AXSM [https://seekingalpha.com... Full story